Investing.com - Regeneron Pharma (NASDAQ:REGN) reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $6.6 on revenue of $1.83B. Analysts polled by Investing.com anticipated EPS of $6.17 on revenue of $1.77B. That with comparison to EPS of $4.45 on revenue of $1.71B in the same period a year before. Regeneron Pharma had reported EPS of $7.5 on revenue of $2.17B in the previous quarter. Analysts are expecting EPS of $5.78 and revenue of $1.67B in the upcoming quarter.
Regeneron Pharma shares are up 44% from the beginning of the year , still down 5.61% from its 52 week high of $574.00 set on April 24. They are outperforming the S&P 500 which is down 12.39% year to date.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma's report follows an earnings beat by J&J on April 14, who reported EPS of $2.3 on revenue of $20.69B, compared to forecasts EPS of $2.02 on revenue of $19.73B.
Pfizer had beat expectations on April 28 with first quarter EPS of $0.8 on revenue of $12.03B, compared to forecast for EPS of $0.73 on revenue of $11.81B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar